lockProducts / InfographicInterleukin 17-A (IL-17A) in Psoriasis
A cornerstone cytokine (messenger protein) involved in the development of psoriasis and other autoimmune diseases.
lockProducts / InfographicInterleukin 17-A (IL-17A) in Inflammatory Joint Disease
IL-17A helps fight infection but in chronic inflammatory joint diseases, IL-17A is a key cytokine involved in disease development.
ImagelockProducts / ImageKymriah® (tisagenlecleucel) suspension for intravenous infusion
Photo of Kymriah™ (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019.
lockProducts / Fact SheetRTH258 Brolucizumab Clinical Trials
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness.
lockProducts / Fact SheetKymriah® (tisagenlecleucel) in children and young adults with B-cell ALL that is refractory or relapsed at least twice
Kymriah® (pronounced: Kim-RYE-ah) is the first FDA-approved CAR-T cell therapy available in the US
lockProducts / Fact SheetThe JULIET Clinical Trial
The JULIET clinical trial is a global, multi-center Phase II registration trial investigating CTL019 (tisagenlecleucel) for use in diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma (NHL). The Novartis-sponsored JULIET trial was conducted in collaboration with the University of Pennsylvania to evaluate the safety and efficacy of CTL019 in adult patients with relapsed or refractory (r/r) DLBCL. Relapsed/refractory DLBCL is an aggressive (fast-growing), complex and difficult-to-treat disease, and patients with DLBCL often have worse prognosis than other forms of NHL.
lockProducts / Fact SheetHow does ACZ885 work?
ACZ885 is a human monoclonal antibody, which is a protein that is designed to bind to only one substance in the body. ACZ885 is designed to bind to human interleukin-1β (IL-1β).
lockProducts / Fact SheetErenumab (AMG 334) Key Clinical Trials By The Numbers
Erenumab has been studied in several large, global, randomized, double-blind, placebo-controlled studies to assess its safety and efficancy in migraine prevention.
lockProducts / Fact SheetAbout erenumab AMG 334
Erenumab is designed to specifically block the CGRP receptor, which plays a critical role in migraine activation. It is being co-developed by Novartis and Amgen.
VideolockCorporate Responsibility / VideoWhat do you know about noncommunicable diseases?
The menace of noncommunicable diseases (NCDs) like cardiovascular disease, diabetes and cancer in the developing world is increasing. New solutions like Novartis Access are needed to ensure more people are trained to prevent, diagnose and treat these diseases, and patients have access to affordable quality medicines.
VideolockDisease education / VideoThe Museum of MS
Welcome to the first-ever Museum of MS, a place that celebrates how people living with multiple sclerosis (MS) overcome the challenges or adapt to the symptoms of MS in their daily lives.
VideolockCorporate Responsibility / VideoNovartis and the International Red Cross partner to provide medicines to Syrian refugees
Novartis Access is partnering with the International Committee of the Red Cross to provide access to medicines for Syrian refugees and their host communities in Lebanon.